Zacks Investment Research on MSN
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
CRISPR Therapeutics CRSP reported a third-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus Estimate of ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...
Investor's Business Daily on MSN
Why Gene-Editing Giants Crispr And Intellia Just Surged
At American Heart Association conference in New Orleans, Crispr Therapeutics CRSP said a single dose of its gene-editing drug ...
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...
The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...
Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback